Newly confident, they're climbing the Asia BusinessWeek 50 with global ambitions.
Market expert Pranav Sanghavi shares some valuable tips.
Ranbaxy Laboratories, India's biggest drugmaker, may lose as much as $140 million of revenue in 2009 after the US drug regulator blocked sale of more than 30 generic medicines and 7 APIs made in two factories of the company, according to analysts.
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
The company is entering into 'risk and reward sharing arrangements' with Indian drug makers which are converting from a generic model to one based on R&D.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
The Indian pharmaceutical companies are involved in patent litigations of a mere 40 drugs, out of the 135 known patent litigation drugs in the US. This is despite the claims by major Indian players such as Ranbaxy and Dr Reddy's at having secured over 20 first to file status abbreviated new drug applications with the US Food and Drug Administration.
Generic drug sales in the US, that power the business of such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, will face competition soon, as big US wholesalers decide to outsource their requirements from upcoming Indian manufacturers.
The interim order was passed by the court on Wednesday on a plea filed by Roche Scientific on January 19 this year. The generic name of the drug is Erlotnib, which Roche markets as Tarceva and Cipla as Erlocip. Ahead of the next hearing, the court has asked Cipla to maintain records of sales of Erlocip.
According to industry experts, individual entrepreneurs are uniting to offer a uniform retail experience.
Ranbaxy Pharmaceuticals Inc said on Tuesday it has received US Food and Drug Administration's approval for manufacturing and marketing cardiovascular drug -- Atenolol tablets in the US.
Analysts feel this decision is yet another example of big-ticket acquisitions turning sour for Indian pharma firms, as happened in the case of Dr Reddy's acquisition of Betapharm of Germany for Rs 2,250 crore (Rs 22.5 billion).
Indian pharma company Lupin has acquired 80 per cent stake in Kyowa Pharmaceutical Industry (Kyowa), one of the top 10 generic pharmaceutical companies in Japan, for an undisclosed amount.
The term 'wiki' is a generic term, meaning a web site where anyone can change any page at any time. Wikipedia, founded by Jimmy Wales, is the eighth most popular website globally. He spent around $2 million (around Rs 8 crore) to maintain the site in 2007.
Shares of Ranbaxy Laboratories on Thursday fell 7.67 per cent on the Bombay Stock Exchange to Rs 552.25 at close, after top investment banks like JP Morgan and CLSA said the out-of-court settlement with Pfizer over cholesterol pill Lipitor announced on Wednesday would delay the launch of the drug in the US by well over a year.
Tiger Woods on Friday pleaded guilty in a Florida court to reckless driving and entered a programme for first-time offenders, avoiding a conviction on the charge of driving under the influence (DUI) last spring.
The E's nature is genteel, more upscale and assured. And that's what most people who gravitate towards the three-pointed star want. It's just that attaining that experience has become that much more accessible with these two new variants.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
The drugmaker has enjoyed big success with low-cost alternatives to AIDS and other high-priced drugs. But NGOs are taking away sales.
India needs to sustain a GDP growth rate of 8 per cent to become a five trillion dollar economy by 2025, the Economic Survey has stated.
In a development that might result in India's leading drug maker Ranbaxy selling a generic version of Pfizer's blockbuster drug Lipitor sooner than expected in the US market, the United States patent office has made an initial rejection of Pfizer's claim on the basic patent on Lipitor.
The sample size of 8,100 farmers across 19 states has not changed in the last three decades, and the methodology of the sample survey too remains unchanged
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Irrational behaviour, born out of incomplete understanding, biases, overconfidence, fear or greed, has led investors to make less than half of what they could have in the capital markets, says Erik Hon.
Eli Lilly and Company, the US-based multinational pharmaceutical major, has sued Sun Pharmaceuticals in the US, alleging the company infringed its patent on Gemzar, a blockbuster cancer drug.
Interestingly, the European Patent Office is yet to grant a patent for Maraviroc, citing insufficient data, sources said. These were the main reasons cited by the Indian Patent Office for rejecting the patent for the cancer drug Gleevec, which snowballed into a global patent battle between the Swiss drug major Novartis and the Indian government.
Under the terms of the deal Ranbaxy will drop litigation it initiated in November 2005 and will sell Nexium from May 2014 - the expiry date of the first of a series of patents. Under US law Ranbaxy would be the exclusive generic distributor for the first six months.
Premium British ale brands such as Abbot Ale, Fuller's London Pride, Broughton, St. Peter's, Spitfire and Hobgoblin Ale are expected to make their entry into the hotels soon.
The branding initiative coincides with the company's expansion.
"The product technology is coming from DNDi. Cipla will manufacture and make the product available in southeast Asia and other parts of the world at affordable pre-agreed prices," Amar Lulla, joint managing director, Cipla, said.
K Anji Reddy from a small village near Vijaywada, quit his job with the government-owned Indian Drugs and Pharmaceuticals Limited in 1974 to set up his own company. The rest is history.
Sun Pharma stated the company wanted shareholders' approval to "issue, offer and allot equity shares or non-convertible securities, other than warrants, up to an amount of Rs 12,000 crore ($2 billion), to qualified institutional buyers pursuant to a QIP."
But, the process patent that existed previously had already allowed for a huge number of cheaper generics. Even so, within two months, Pfizer's Viagra had exceeded its own expectations by capturing 1.8 per cent of the market, worth around Rs 80 crore (Rs 800 million). It set an example and gave hope to other pharma companies to launch their products in India.
Wockhardt's US subsidiary, Wockhardt USA, has launched Ondansetron injection in the United States on December 26.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
Medicines produced in India have become a lifeline for people living in developing countries around the world.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
After raising its stake to 100% in UK JV; the firm plans to expand European portfolio with new products.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances